Urology News and Research

Latest Urology News and Research

ACS honors Boston pediatric surgeon with 2012 Jacobson Innovation Award

W. Hardy Hendren III, MD, FACS, FRCS (Ire, Eng, Glas) (Hon), a pediatric surgeon from Boston, Mass., received the 2012 Jacobson Innovation Award of the American College of Surgeons (ACS) at a dinner held in his honor tonight in Chicago, Ill.

14 Jun 2012

Compounds related to curcumin receive U.S. patent

A U.S patent issued today to the University of Rochester and two other entities for the use of compounds related to a popular spice in the fight against cancer, acne, baldness, and other medical conditions.

13 Jun 2012

DNDi, Astellas partner on new drug discovery research for treatment of NTDs

Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.

12 Jun 2012

VHC extends Obstetrics services to Kaiser Permanente members

Virginia Hospital Center announced today an expansion of services offered at Virginia Hospital Center, to include Obstetrics for Kaiser Permanente's members.

11 Jun 2012

Second-hand cigarette smoke linked with moderate to severe urinary disorders in children

According to the Environmental Protection Agency, parents are responsible for 90 percent of children's exposure to environmental (second-hand) tobacco smoke. Children with mothers who smoke are at even higher-risk for developing health disorders.

8 Jun 2012

Tp53 genetic mutation may play an important role in prostate cancer

A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.

8 Jun 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer.

5 Jun 2012

LifePoint to acquire Woods Memorial Hospital

The Woods Memorial Hospital Board of Directors today announced it has signed an asset purchase agreement for the acquisition of the hospital by LifePoint Hospitals, a leading hospital company focused on providing quality healthcare close to home.

5 Jun 2012

$Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML$

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations.

5 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

Study identifies several proteins as new therapeutic targets and biomarkers for kidney cancer

Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors.

2 Jun 2012

First U.S.-based study to assess per-patient annual economic costs of fecal incontinence

Care for patients with fecal incontinence costs $4,110 per person for both medical and non-medical costs like loss of productivity, according to new research from the University of Michigan.

2 Jun 2012

European Multidisciplinary Meeting on Urological Cancers to be held in Barcelona

With the goal to deliver an in-depth review of the latest multi-modal management strategies for urological cancers, the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) will be held from 16 to 18 November 2012 in Barcelona, Spain.

2 Jun 2012

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.

31 May 2012

Surprising life-quality benefit from early prostate cancer treatment

Treatment of early-stage prostate cancer may also improve quality of life if patients have previously suffered from obstructive urinary symptoms before undergoing treatment, shows US research.

30 May 2012

Dehydration: how much should we drink per day?

As the northern hemisphere approaches the summer months, many of us begin to think about drinking more to prevent dehydration. But exactly how much should we be drinking a day? Does the amount vary depending on what we are drinking? And what happens if we don’t drink enough fluid?

30 May 2012

Endo, Watson reach agreement to resolve two LIDODERM patent infringement lawsuits

Endo announced today that it has reached an agreement with Watson Pharmaceuticals (Watson) resolving two patent infringement lawsuits related to LIDODERM.

30 May 2012

Watson, Endo and Teikoku Seiyaku enter settlement agreement to resolve Lidoderm patent litigation

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an agreement with Endo Pharmaceuticals Inc. and Teikoku Seiyaku Co., Ltd to settle all outstanding patent litigation related to Watson's generic version of Lidoderm.

29 May 2012

UCLA geneticists identify mutation responsible for IMAGe syndrome

UCLA geneticists have identified the mutation responsible for IMAGe syndrome, a rare disorder that stunts infants' growth. The twist? The mutation occurs on the same gene that causes Beckwith-Wiedemann syndrome, which makes cells grow too fast, leading to very large children.

28 May 2012

Auxilium, FCB I file suit against Watson over generic Testim

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals, Inc.'s Testim 1%.

25 May 2012

Urology News and Research

Latest Urology News and Research

ACS honors Boston pediatric surgeon with 2012 Jacobson Innovation Award

Compounds related to curcumin receive U.S. patent

DNDi, Astellas partner on new drug discovery research for treatment of NTDs

VHC extends Obstetrics services to Kaiser Permanente members

Second-hand cigarette smoke linked with moderate to severe urinary disorders in children

Tp53 genetic mutation may play an important role in prostate cancer

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

LifePoint to acquire Woods Memorial Hospital

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Study identifies several proteins as new therapeutic targets and biomarkers for kidney cancer

First U.S.-based study to assess per-patient annual economic costs of fecal incontinence

European Multidisciplinary Meeting on Urological Cancers to be held in Barcelona

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Surprising life-quality benefit from early prostate cancer treatment

Dehydration: how much should we drink per day?

Endo, Watson reach agreement to resolve two LIDODERM patent infringement lawsuits

Watson, Endo and Teikoku Seiyaku enter settlement agreement to resolve Lidoderm patent litigation

UCLA geneticists identify mutation responsible for IMAGe syndrome

Auxilium, FCB I file suit against Watson over generic Testim

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Urology News and Research

Latest Urology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in